Obama administration: no plans to bifurcate food/tobacco from drugs/devices

Share this article:
When it comes to the future of the FDA, sources inside the Obama administration assure me that they have no plans to bifurcate food/tobacco from drugs/devices. In other words, commissioner Margaret Hamburg and principal deputy commissioner Joshua Sharfstein will act as a team in addressing the direction of the FDA as a totality. We'll see.

That being said, this remains as contentious as ever, with Reps. Henry Waxman and Rosa DeLauro agreeing to disagree. Waxman believes that the “first step on the legislative path” should be shoring up food safety and finding ways to prevent further incidents. According to the Pink Sheet, “Waxman did suggest that he would entertain the concept of a bifurcated agency in the future. Once reforms are passed and implemented, he suggested Congress could consider ‘whether reorganization is necessary' for food safety enforcement.” But DeLauro has introduced the Food Safety Modernization Act, which would move some divisions out of FDA and form a Department of Health and Human Services agency for food safety. 

That being said, a dangerous bifurcation that must be avoided at all costs is a differentiation in the vision for the future of the FDA between appointees and career staff.  Hamburg and Sharfstein should listen and learn from the agency's senior staff—most specifically as to how the agency can be both regulator and colleague with the industries it regulates.  A fine line to walk—but a journey worth the effort.

A shared vision, crafted together will succeed.  Unity, yes.  Bifurcation, no. Yes we can.

Peter J. Pitts is president of the Center for Medicine in the Public Interest, a former FDA associate commissioner and partner/director of global healthcare at Porter Novelli
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?